$SNDX
Syndax Pharmaceuticals Inc

2018 Q1 Form 10-K Financial Statement

#000156459018004911 Filed on March 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017
Revenue $379.0K $1.193M $2.108M
YoY Change 24.26% 291.15% 72.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.790M $4.080M $15.86M
YoY Change 21.88% 37.37% 19.07%
% of Gross Profit
Research & Development $15.34M $16.60M $48.20M
YoY Change 60.58% 95.88% 52.22%
% of Gross Profit
Depreciation & Amortization $150.0K $76.00K
YoY Change 66.67% -14.61%
% of Gross Profit
Operating Expenses $20.13M $20.68M $64.06M
YoY Change 49.31% 80.69% 42.4%
Operating Profit -$19.75M -$19.49M -$61.95M
YoY Change 49.89% 74.93% 41.56%
Interest Expense $475.0K $460.0K $1.421M
YoY Change 83.4% 70.37% 48.64%
% of Operating Profit
Other Income/Expense, Net $353.0K $385.0K $1.152M
YoY Change 71.36% 18.1% -263.17%
Pretax Income -$19.40M -$19.10M -$60.80M
YoY Change 49.58% 76.52% 36.72%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$19.40M -$19.10M -$60.80M
YoY Change 49.55% 76.64% 36.72%
Net Earnings / Revenue -5118.21% -1601.34% -2884.35%
Basic Earnings Per Share
Diluted Earnings Per Share -$792.5K -$796.5K -$2.895M
COMMON SHARES
Basic Shares Outstanding 24.70M 24.39M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.0M $131.3M $131.3M
YoY Change 19.75% 22.71% 22.71%
Cash & Equivalents $28.20M $35.17M $35.20M
Short-Term Investments $86.00M $96.10M $96.10M
Other Short-Term Assets $5.000M $1.800M $1.800M
YoY Change 212.5% 50.0% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $119.3M $133.4M $133.4M
YoY Change 22.92% 22.98% 22.95%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $267.0K $300.0K
YoY Change 70.94% 2.69% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.200M $3.200M
YoY Change
Other Assets $200.0K $231.0K $200.0K
YoY Change -46.81% -4.94% 0.0%
Total Long-Term Assets $700.0K $3.744M $3.800M
YoY Change 14.75% 644.33% 660.0%
TOTAL ASSETS
Total Short-Term Assets $119.3M $133.4M $133.4M
Total Long-Term Assets $700.0K $3.744M $3.800M
Total Assets $120.0M $137.2M $137.2M
YoY Change 22.87% 25.84% 25.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $2.232M $2.200M
YoY Change -5.14% -6.02% -8.33%
Accrued Expenses $12.80M $12.00M $12.00M
YoY Change 82.86% 76.47% 76.47%
Deferred Revenue $1.573M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.90M $15.80M $15.80M
YoY Change 53.79% 52.4% 51.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.10M $310.0K $17.10M
YoY Change 10778.38% 7.64% 17.93%
Total Long-Term Liabilities $16.10M $17.07M $17.10M
YoY Change 14.48% 17.65% 17.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.90M $15.80M $15.80M
Total Long-Term Liabilities $16.10M $17.07M $17.10M
Total Liabilities $33.00M $32.87M $32.90M
YoY Change 31.73% 32.13% 32.13%
SHAREHOLDERS EQUITY
Retained Earnings -$366.1M
YoY Change 19.92%
Common Stock $470.6M
YoY Change 20.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $86.95M $104.3M $104.3M
YoY Change
Total Liabilities & Shareholders Equity $120.0M $137.2M $137.2M
YoY Change 22.87% 25.84% 25.87%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017
OPERATING ACTIVITIES
Net Income -$19.40M -$19.10M -$60.80M
YoY Change 49.55% 76.64% 36.72%
Depreciation, Depletion And Amortization $150.0K $76.00K
YoY Change 66.67% -14.61%
Cash From Operating Activities -$19.87M -$12.72M -$47.37M
YoY Change 56.83% 22.07% 34.74%
INVESTING ACTIVITIES
Capital Expenditures $173.0K -$40.00K $84.00K
YoY Change -67.82%
Acquisitions
YoY Change
Other Investing Activities $12.82M $1.590M -$16.99M
YoY Change 15.91% -92.55% -6.24%
Cash From Investing Activities $12.64M $1.550M -$17.07M
YoY Change 14.32% -92.73% -6.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.00K 25.61M 75.72M
YoY Change -72.5% 14964.71% 39.7%
NET CHANGE
Cash From Operating Activities -19.87M -12.72M -47.37M
Cash From Investing Activities 12.64M 1.550M -17.07M
Cash From Financing Activities 33.00K 25.61M 75.72M
Net Change In Cash -7.193M 14.44M 11.28M
YoY Change 367.99% 30.32% 1380.18%
FREE CASH FLOW
Cash From Operating Activities -$19.87M -$12.72M -$47.37M
Capital Expenditures $173.0K -$40.00K $84.00K
Free Cash Flow -$20.04M -$12.68M -$47.46M
YoY Change 58.19% 21.69% 33.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
231000
CY2017Q4 us-gaap Assets
Assets
137186000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11993000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15798000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10366000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
288000
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14508000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35168000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
106000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2232000
CY2016Q4 us-gaap Liabilities
Liabilities
24874000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
389374000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
56000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-305293000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
84139000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109013000
CY2017Q2 dei Entity Public Float
EntityPublicFloat
117100000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23844000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
151000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
94806000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
81486000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3029000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
108510000
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
3246000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
260000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
243000
CY2016Q4 us-gaap Assets
Assets
109013000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2375000
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6771000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1573000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1220000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
16759000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14220000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
470571000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24390033
CY2017 us-gaap Licenses Revenue
LicensesRevenue
2108000
CY2016 us-gaap Licenses Revenue
LicensesRevenue
1220000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
627000
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
2108000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
1220000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
627000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48201000
CY2016 us-gaap Operating Expenses
OperatingExpenses
44986000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-61954000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-43766000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24697944
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44444000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-252415000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9549000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15861000
CY2017 us-gaap Operating Expenses
OperatingExpenses
64062000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31665000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13321000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3362000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
133442000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
267000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
310000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
17069000
CY2017Q4 us-gaap Liabilities
Liabilities
32867000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-143000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-366111000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
104319000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137186000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18215181
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11591000
CY2015 us-gaap Operating Expenses
OperatingExpenses
21140000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-199000
CY2015 us-gaap Depreciation
Depreciation
21000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1629000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1205000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1045000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-303000
CY2015 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1940000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3882000
CY2015 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
923000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4842000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261000
CY2017 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
97000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2058000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
191000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10009000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3882000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
28000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-20513000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1421000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
956000
CY2017 us-gaap Depreciation
Depreciation
76000
CY2016 us-gaap Depreciation
Depreciation
89000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-223000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
126000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
5450000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
4708000
CY2017 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000
CY2016 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
329000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5305000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
277000
CY2016 sndx Convertible Preferred Stock Accretion Of Dividends
ConvertiblePreferredStockAccretionOfDividends
2598000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50527000
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
321711000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4551000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1414000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1703000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2155000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-269000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-37000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1152000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-706000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3606000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-60802000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-44472000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-24119000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60802000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47070000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-103845000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.90
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.22
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1519.27
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20997211
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14619716
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68352
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61001000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24091000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-152569000
CY2015 sndx Convertible Preferred Stock Accretion To Redemption Value Adjustment
ConvertiblePreferredStockAccretionToRedemptionValueAdjustment
69715000
CY2015 sndx Convertible Preferred Stock Accretion Of Dividends
ConvertiblePreferredStockAccretionOfDividends
10011000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75000
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
14000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2058000
CY2016 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
42000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4708000
CY2016 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
1000
CY2017 sndx Stock Issued During Period Value Follow On Offering Net Of Offering Cost
StockIssuedDuringPeriodValueFollowOnOfferingNetOfOfferingCost
48675000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
277000
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
59000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5450000
CY2017 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
1705000
CY2017 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
97000
CY2017 sndx Stock Issued During Period Value Direct Stock Placement Net
StockIssuedDuringPeriodValueDirectStockPlacementNet
24918000
CY2017 sndx Adjustments To Additional Paid In Capital Follow On Offering Cost
AdjustmentsToAdditionalPaidInCapitalFollowOnOfferingCost
3665000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
762000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2892000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1220000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16660000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-47371000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35157000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2428000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
CY2017 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-45000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
97000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
118000
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
152263000
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
158319000
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
102008000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
135275000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
140297000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
40506000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17027000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18380000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-61669000
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
52148000
CY2015 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
87323000
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1245000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
9000000
CY2016 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-4000
CY2015 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75722000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
54202000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
77267000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11324000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
665000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13170000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23179000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Syndax Pharmaceuticals, Inc. (the Company) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company is developing its lead product candidate, entinostat, a once-weekly, oral, small molecule, Class I HDAC inhibitor, in combination with exemestane and several approved PD-1/PD-L1 antagonists. The Company&#8217;s pipeline also includes SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, as well as a portfolio of potent and selective inhibitors targeting the binding interaction of Menin with MLLr. The Company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the Company completed its initial public offering (&#8220;IPO&#8221;) whereby it sold 4,809,475 shares of common stock at the initial public offering price of $12.00 per share, which included 409,475 shares issued pursuant to the underwriters&#8217; partial exercise of their over-allotment option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were $50.5 million, net of underwriting discounts and commissions of $4.0 million and offering expenses of $3.1 million. Upon the closing of the IPO, all outstanding shares of the Company&#8217;s outstanding convertible preferred stock converted into 12,872,551 shares of common stock; and the Company&#8217;s outstanding warrant liability to purchase 357,840 shares of the Company&#8217;s common stock valued at $4.6 million was reclassified to additional paid-in capital. The shares trade on the Nasdaq Global Select Market under the symbol &#8220;SNDX.&#8221;&#160;In connection with the closing of the Company&#8217;s IPO, the Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both of which were approved by the Company&#8217;s board of directors and stockholders on September&#160;28, 2015 and February&#160;24, 2016, respectively. Pursuant to the amended and restated certificate of incorporation, the Company is now authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, the Company entered into a sales agreement with Cowen and Company, LLC (&#8220;Cowen&#8221;) under which the Company may issue and sell shares of our common stock having aggregate sales proceeds of up to $50.0 million from time to time through Cowen, acting as agent, in a series of one or more at-the-market (&#8220;ATM&#8221;) equity offerings. Cowen is not required to sell any specific amount but acts as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. Shares sold pursuant to the sales agreement will be sold pursuant to a shelf registration statement, which became effective on April 20, 2017. Our common stock will be sold at prevailing market prices at the time of the sale; and as a result, prices may vary. We will pay Cowen up to 3% of the gross proceeds from any common stock sold through the sales agreement. In 2017, the Company sold 148,421 shares of Common Stock pursuant to the ATM program, at an average price of $12.45 per share for gross proceeds of $1.8 million, resulting in net proceeds of $1.7 million after deducting sales commissions and offering expenses. As of December 31, 2017, $48.2 million of Common Stock remained available for sale under the ATM program.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the Company completed a follow-on public offering whereby the Company sold 3,950,190 shares of common stock at a price of $13.25 per share, which included 200,190 shares issued pursuant to the underwriters&#8217; partial exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $48.7 million, net of underwriting discounts and commissions and estimated offering expenses payable by the Company.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 13, 2017, the Company entered into a license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc (&#8220;Allergan&#8221;), under which Allergan granted to the Company a worldwide, sublicenseable, exclusive license to a portfolio of preclinical, orally-available, small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia (&#8220;MLL&#8221;) protein (the &#8220;Menin Assets&#8221;). The Company made a nonrefundable upfront payment of $5.0 million to Allergan in the fourth quarter of 2017. The Company is developing the Menin Assets to potentially treat MLL-r driven malignancies and believes that the Menin Assets have the potential to be used to treat a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (&#8220;MLL-r&#8221;). The Company is in the process of performing a number of pre-clinical studies related to the Menin Assets.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:2pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 17, 2017, the Company entered into a purchase agreement with Biotech Value Fund, L.P. (&#8220;BVF&#8221;) and certain entities affiliated with BVF (the &#8220;Purchase Agreement&#8221;). Pursuant to the Purchase Agreement, the Company issued directly to BVF in a registered direct offering (the &#8220;Offering&#8221;), 2,021,018 shares of the Company&#8217;s common stock at a price of $12.37 per share, representing the closing price of the Company&#8217;s shares on the Nasdaq Global Select Market on Friday, October 13, 2017. The net proceeds from the Offering, after deducting estimated expenses, were $24.9 million.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company&#8217;s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it will be several years before any of its product candidates is approved, if ever, and the Company begins to generate revenue from sales of such product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of its product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management believes that the cash, cash equivalents, short-term and long-term investments balances as of December&#160;31, 2017 should enable the Company to maintain its planned operations for at least twelve&#160;months from the date these financial statements were issued. The Company&#8217;s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities. </p></div>
CY2016Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Cash and cash equivalents, restricted cash, and short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. Substantially all of the Company&#8217;s cash, cash equivalents, and short-term and long-term investments were deposited in accounts at two financial institutions, and at times, such deposits may exceed federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s available-for-sale investments primarily consist of U.S. Treasury securities, U.S. government agency securities, corporate debt securities, certificates of deposit and overnight deposits and potentially subject the Company to concentrations of credit risk. </p></div>
CY2017 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.22%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Guarantees and Indemnifications </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">As permitted under Delaware law, the Company indemnifies its officers, directors, and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. The Company has standard indemnification arrangements under office leases (as described in Note 16) that require it to indemnify the landlord against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation, or nonperformance of any covenant or condition of the Company&#8217;s lease. Through December&#160;31, 2017, the Company had not experienced any losses related to these indemnification obligations and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations, and consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p></div>
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
2598000
CY2015 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
10011000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108248000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
81486000
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1286000
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1630000
CY2017Q4 us-gaap Supplies
Supplies
220000
CY2016Q4 us-gaap Supplies
Supplies
461000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
69715000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
466000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
540000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
199000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
280000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108391000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
81430000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
67000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
143000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
CY2017Q2 sndx Payment Specified Percentage Of Gross Proceeds From Sale Of Shares
PaymentSpecifiedPercentageOfGrossProceedsFromSaleOfShares
0.03
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0
CY2017Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
377000
CY2016Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
306000
CY2017Q4 sndx Reimbursable Costs
ReimbursableCosts
1029000
CY2016Q4 sndx Reimbursable Costs
ReimbursableCosts
262000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
192000
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
168000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
258000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
265000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
247000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2393000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1641000
CY2017Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9177000
CY2016Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
4493000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
390000
CY2014Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5498310
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5450000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4708000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3882000
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P6Y7D
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y10M6D
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y10M20D
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7386
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7140
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6992
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0202
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0141
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0173
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2560737
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
967490
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
46680
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
89715
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3391832
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1943661
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3371831
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.97
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.22
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.93
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.03
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.28
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.66
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.27
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
503000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2688000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2173000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2688000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.68
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.94
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.74
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
441573
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
41607
CY2016 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
16731
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3800000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
106000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2160000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
3000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
72000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
33000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11091000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13744000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2380000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1739000
CY2017Q4 sndx Deferred Tax Assets Capitalized Startup And Costs Research And Development Costs
DeferredTaxAssetsCapitalizedStartupAndCostsResearchAndDevelopmentCosts
43282000
CY2016Q4 sndx Deferred Tax Assets Capitalized Startup And Costs Research And Development Costs
DeferredTaxAssetsCapitalizedStartupAndCostsResearchAndDevelopmentCosts
47048000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3240000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5420000
CY2017Q4 sndx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
8610000
CY2016Q4 sndx Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
10530000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
534000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
604000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2530000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2298000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54447000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
60323000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54447000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
60323000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5900000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13000000
CY2017 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
The Company has provided a valuation allowance for the full amount of the net deferred tax assets as the realization of the deferred tax assets is not determined to be more likely than not. The valuation allowance increased by $13.0 million in 2016, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards and capitalized research and development costs, and decreased by $5.9 million in 2017 due to the decrease in the federal tax rate.
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
44900000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
26000000
CY2017 sndx Deferred Tax Assets Operating Loss Carryforwards Expiration Period
DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod
2037
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 sndx Tax Cuts And Jobs Act Of2017 Accounting Complete
TaxCutsAndJobsActOf2017AccountingComplete
false
CY2017 sndx Tax Cuts And Jobs Act Of2017 Incomplete Accounting Transition Tax For Accumulated Foreign Earnings Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit
0
CY2017 sndx Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
-28800000
CY2017 sndx Tax Cuts And Jobs Act Of2017 Incomplete Accounting Reduction In Deferred Tax Assets Valuation Allowance
TaxCutsAndJobsActOf2017IncompleteAccountingReductionInDeferredTaxAssetsValuationAllowance
28800000
CY2017 sndx Tax Cuts And Jobs Act Of2017 Incomplete Accounting Reduction In Deferred Tax Assets Valuation Allowance Net
TaxCutsAndJobsActOf2017IncompleteAccountingReductionInDeferredTaxAssetsValuationAllowanceNet
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
241000
CY2017 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
78000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
163000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
549000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
569000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
588000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
395000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
59000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
0
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22239996
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
358000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
3000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
0
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
3000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
100000
CY2016 us-gaap Interest Paid
InterestPaid
2000
CY2015 us-gaap Interest Paid
InterestPaid
688000
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
5211000
CY2017 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
50000
CY2015 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
376000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
27000
CY2017 sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
59000
CY2016 sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
42000
CY2015 sndx Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
14000
CY2016 sndx Reclassification Of Common Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital
4551000
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
328941000
CY2017Q1 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2017Q2 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2017Q3 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2017Q4 us-gaap Licenses Revenue
LicensesRevenue
1193000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9552000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9862000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12188000
CY2017Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16599000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3930000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4285000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3563000
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4083000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13482000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
14147000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
15751000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
20682000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13177000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13842000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15446000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19489000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
206000
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
203000
CY2017Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
385000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12971000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-13639000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-15088000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-19104000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.80
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18231602
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19497581
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23943241
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2972000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
9058000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
8939000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
15543000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
11446000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8753000
CY2016Q1 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q4 us-gaap Licenses Revenue
LicensesRevenue
305000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4786000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12274000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8474000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4272000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2808000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3269000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8634000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15238000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-11141000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1577000
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
276000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
269000
CY2016Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
326000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10330000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-8358000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14969000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-10815000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.85
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4541536
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17769514
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17899481
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18193027

Files In Submission

Name View Source Status
0001564590-18-004911-index-headers.html Edgar Link pending
0001564590-18-004911-index.html Edgar Link pending
0001564590-18-004911.txt Edgar Link pending
0001564590-18-004911-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030818401888146701.jpg Edgar Link pending
g2018030818401963246702.jpg Edgar Link pending
g2018030818401963946703.jpg Edgar Link pending
g2018030818401967446704.jpg Edgar Link pending
g2018030818401973846705.jpg Edgar Link pending
g2018030818404250446706.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10k_20171231.htm Edgar Link pending
sndx-20171231.xml Edgar Link completed
sndx-20171231.xsd Edgar Link pending
sndx-20171231_cal.xml Edgar Link unprocessable
sndx-20171231_def.xml Edgar Link unprocessable
sndx-20171231_lab.xml Edgar Link unprocessable
sndx-20171231_pre.xml Edgar Link unprocessable
sndx-ex1034_508.htm Edgar Link pending
sndx-ex1047_509.htm Edgar Link pending
sndx-ex231_9.htm Edgar Link pending
sndx-ex311_8.htm Edgar Link pending
sndx-ex312_10.htm Edgar Link pending
sndx-ex321_11.htm Edgar Link pending